Monograph
J07AM01 - Tetanus Toxoid |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the Tetanus toxoid vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Tetanus toxoid.
Therapeutic characteristics
Prophylaxis against tetanus.
It is administered by intramuscular injections, in primary immunization series usually according to a three dose schedule. Single booster doses may be recommended every 10 years or in tetanus prone injuries.
Metabolism and pharmacokinetics
The tetanus toxoid vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
One report of a possible acute porphyric attack in a female with AIP, but the attack was poorly documented and there were other concomittant factors that could cause the attack. This report has therefore not been taken into account in the judgement of the porphyrinogenicity of the vaccine.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Tetavax.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
United Kingdom
Denmark
Norway
Poland
Serbia© NAPOS 2024